Loading...
Loading...
Shares of Actavis
ACT are up 2.3 percent to $198.42 in Wednesday's trading after Sterne Agee initiated coverage on the stock with a Buy rating and $230 price target.
Analyst Shibani Malhotra sees upside “to the company's pro-revenue and synergy targets, and expects management to continue to implement on its disciplined inorganic growth strategy.”
The analyst is also bullish on the company's growth profile “post its recent merger with Forest Laboratories
FRX.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in